<DOC>
	<DOCNO>NCT01852565</DOCNO>
	<brief_summary>Darapladib ( SB-480848 ) novel , selective , orally active inhibitor lipoprotein associate phospholipase A2 ( Lp-PLA2 ) currently clinical development GlaxoSmithKline potential anti-atherosclerosis agent reduction major adverse cardiovascular ( CV ) event patient population chronic coronary heart disease acute coronary syndrome . This study determine effect repeat administration diltiazem pharmacokinetics repeat administration darapladib . A drug interaction study moderate CYP3A4 inhibitor warrant provide guidance prescribe physician .</brief_summary>
	<brief_title>Study Determine Effect Repeated Administration Diltiazem Pharmacokinetics Darapladib ( Sb-480848 ) .</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>Male female age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test ECG . A subject alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase bilirubin laboratory result outside reference range may include Investigator GSK Medical Monitor agree document find unlikely introduce additional risk factor interfere study procedure . BMI within range 1937 kilogram per square meter ( kg/m2 ) ( inclusive ) . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy [ definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ] ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit per milliliter ( MlU/ml ) estradiol &lt; 40 picogram/milliliter [ ( pg/ml ) ( &lt; 147 pmol/L ) confirmatory ] . A female subject eligible participate Childbearing potential abstinent agree use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception final followup visit . A female subject eligible participate Childbearing potential samesex partner , prefer usual lifestyle . Capable give write informed consent , include compliance requirement restriction list consent form Single QT duration correct heart rate Fridericia 's formula ( QTcF ) &lt; 450 Millisecond ( msec ) A subject eligible inclusion study follow criterion apply : Criteria Based Upon Medical Histories Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 ml ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , include diltiazem , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Any contraindication diltiazem administration . Any condition , opinion investigator , present undue risk study medication , include diltiazem , procedure . Requiring use oral injectable strong Cytochrome P450 ( CYP3 ) A4 inhibitor use CYP3A4 inhibitor/inducers within 14 day prior dose . History anaphylaxis , anaphylactoid ( resemble anaphylaxis ) reaction Clinical criterion diagnose anaphylaxis severe allergic response . Criteria Based Upon Diagnostic Assessments A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . Pregnant female determine positive human chorionic gonadotropin ( hCG ) test screen prior dosing . Other Criteria Where participation study would result donation blood blood product excess 500 mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Consumption grapefruit grapefruit juice within 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>CYP3A4</keyword>
	<keyword>Lp-PLA2</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>Drug interaction</keyword>
</DOC>